Safety and antibody responses of Omicron BA.4/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study
Issued Date
2024-10-01
Resource Type
eISSN
25901362
Scopus ID
2-s2.0-85200211617
Journal Title
Vaccine: X
Volume
20
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccine: X Vol.20 (2024)
Suggested Citation
Kanokudom S., Chansaenroj J., Suntronwong N., Wongsrisang L., Aeemjinda R., Vichaiwattana P., Thatsanathorn T., Chantima W., Pakchotanon P., Duangchinda T., Sudhinaraset N., Honsawek S., Poovorawan Y. Safety and antibody responses of Omicron BA.4/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study. Vaccine: X Vol.20 (2024). doi:10.1016/j.jvacx.2024.100538 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/100409
Title
Safety and antibody responses of Omicron BA.4/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study
Corresponding Author(s)
Other Contributor(s)
Abstract
This cohort study, conducted between July and August 2023, evaluated the adverse events (AEs) and immune response to a bivalent mRNA-1273.222 (containing sequences of the original Wuhan-H1 strain and the Omicron BA.4/5 variant) booster vaccine in 122 participants. The study included individuals with diverse vaccination histories, and their responses were assessed based on anti-receptor binding domain (RBD) IgG levels and neutralizing antibodies against the wild-type, Omicron BA.5, and XBB.1.16 variants. Following administration of the BA.4/5 bivalent vaccine, AEs were generally mild to moderate and well-tolerated within a few days. There were no reports of vomiting and no serious AEs or death. The findings demonstrated robust immune responses, with significant increases in anti-RBD IgG levels, particularly in groups that had received 3 –6 doses before the booster dose. The BA.4/5 bivalent booster effectively induced neutralizing antibodies against the vaccine strains, providing robust neutralization, including the XBB.1.16 strain. The study also highlighted that individuals with hybrid immunity, especially those assumed infected with the BA.5 strain or who had been infected twice, showed higher levels of robust neutralizing activity against Omicron XBB.1.16. Overall, these results indicate that the BA.4/5 bivalent booster vaccines can induce potent and good antibody responses in emerging Omicron subvariants, supporting its efficacy as a booster in individuals with diverse vaccination histories.